Progress in Multiple Sclerosis Research

Front Matter....Pages I-XIX
Front Matter....Pages 1-1
Applications of Chronic Relapsing Experimental Allergic Encephalomyelitis to the Study of Multiple Sclerosis....Pages 3-10
Chronic Relapsing EAE: Its Application to Study of Human Inflammatory Demyelinating Diseases....Pages 11-17
Refinement of the EAE Model Utilizing Various Synthetic Adjuvants and Bacterial Fractions: An Attempt to Produce a Chronic Model of EAE....Pages 18-27
Discussion....Pages 28-30
Theiler’s Virus Infection of the Central Nervous System of Mice: An Animal Model of Virus-Induced Demyelination....Pages 31-34
Acute and Recurrent Demyelination Induced by Wild-Type and Temperature-Sensitive Mutants of Mouse Hepatitis Virus. Electron-Microscopic Studies....Pages 35-39
Coronavirus Infection in Rats....Pages 40-46
Search for Viral Nucleic Acids in Multiple Sclerosis Brain....Pages 47-52
A Possible Coronavirus Isolation from Multiple Sclerosis Autopsy Material....Pages 53-58
Defective Viral Infection: The Rescue of Virus from Antigen-Negative Cells....Pages 59-62
Some Properties of Cortical Nerve Cells of Adult Rats Bulk Isolated After Brain Perfusion....Pages 63-66
In Vitro Demyelination by Lymphocytes and Lymphokines from Patients and Experimental Animals....Pages 67-72
The Virus-Host Relationship in CNS Model Cells....Pages 73-79
Attempts to Transmit Multiple Sclerosis to Newborn and Germ-Free Nonhuman Primates: A Ten Year Interim Report....Pages 80-85
Front Matter....Pages 87-87
Introduction....Pages 89-89
Production of Interspecies Hybridomas Between CSF or Blood Lymphocytes from Patients with Neurological Diseases and Mouse Myeloma Cells....Pages 90-97
Antibodies to Myelin Basic Protein in Cerebrospinal Fluid of Patients with Multiple Sclerosis....Pages 98-105
Multiple Sclerosis De Novo Central Nervous System IgG Synthesis: Measurement, Antibody Profile, Significance, Eradication, and Problems....Pages 106-116
Evaluation of the Blood/CSF Permeability Coefficients and of the Intrathecal Synthesis of IgG by Capillary Isotachophoresis....Pages 117-122
CSF-Oligoclonal Bands in Multiple Sclerosis....Pages 123-128
Front Matter....Pages 87-87
CSF Findings in Patients with Multiple Sclerosis and Optic Neuritis....Pages 129-131
Oligoclonal Cerebrospinal Fluid Immunoglobulin in Relation to Measles and Parainfluenza Antibody Response in Multiple Sclerosis....Pages 132-141
Oligoclonal Bands in Cerebrospinal Fluid....Pages 142-143
Quantitative Determination of IgG Subclasses in CSF and Serum of MS Patients: Comparison with Other Neurological Diseases and Normal Controls....Pages 144-148
Assessment of Process Activity in Multiple Sclerosis and Changes in Spinal Fluid....Pages 149-153
Evaluation of IgG Synthesis in the Central Nervous System....Pages 154-156
CSF Lipids in Demyelinating Diseases....Pages 157-160
Diagnostic Value of Myelin Basic Protein in Cerebrospinal Fluid....Pages 161-167
Myelin Basic Protein in Cerebrospinal Fluid as an Indicator of MS Process Activity....Pages 168-169
Central and Peripheral Myelin Basic Protein in Cerebrospinal Fluid of Multiple Sclerosis and Other Neurological Disorders....Pages 170-173
The Activity of a Cholesterol Ester Hydrolase in Human Cerebrospinal Fluid....Pages 174-175
Clinical Relevance of the Determination of IgM in the Cerebrospinal Fluid with Special Reference to Multiple Sclerosis Patients....Pages 176-179
Discussion....Pages 180-181
Nucleic and Viral Antibodies in Serum and CSF of MS Patients....Pages 182-188
CSF Proteinase Inhibitors....Pages 189-194
The Occurrence of Immune Complexes in Patients with Multiple Sclerosis....Pages 195-199
Immune Complexes in Cerebrospinal Fluid and Serum of Patients with Multiple Sclerosis....Pages 200-206
Viral-Induced Immunological Incompetence as an Etiologic Factor in Multiple Sclerosis....Pages 207-212
Discussion....Pages 213-215
Approaches to Understanding the Role of Antibody in Multiple Sclerosis....Pages 216-220
Front Matter....Pages 87-87
Partial Purification of MS-Specific Antigens....Pages 221-231
Discussion....Pages 232-234
Studies of Immune Reactions in Multiple Sclerosis by Active T-Rosette Test, Immunofixation, and Myelinotoxicity of Lymphocytes in the Rabbit Eye....Pages 235-243
Antibody-Dependent Cytotoxicity of Lymphocytes Against Basic Protein of Myelin in Multiple Sclerosis....Pages 244-247
New Aspects of Lymphocyte Reactivity and Lymphokine Activity in Multiple Sclerosis....Pages 248-255
Viral Antibody Responses in the Central Nervous System of Patients with Multiple Sclerosis....Pages 256-262
Measles Reactivity in Patients with Multiple Sclerosis....Pages 263-265
Measles Virus Infection of Human Lymphocytes....Pages 266-270
Kinetics of Measles Virus Antibodies in Multiple Sclerosis Patients in Correlation to the Clinical Course of the Disease....Pages 271-277
Longitudinal Studies of Viral Antibody Synthesis in MS Patients....Pages 278-285
Discussion....Pages 286-288
Suppressor Lymphocyte Function During Attacks of Multiple Sclerosis....Pages 289-293
Discussion....Pages 294-295
Purification and Characterization of the T-Cell Antigen Receptor Recognizing the Basic Encephalitogenic Protein....Pages 296-299
Immunological Cell Surface Marker Analysis in Multiple Sclerosis....Pages 300-303
The Enhancing Effect of Multiple Sclerosis Brain Homogenates on Active E-Rosette Forming Lymphocytes in Neurological Disorders. Relationship Between Rosette Formation and Clinical Parameters....Pages 304-309
Recent Methods of in Vitro Diagnosis of Multiple Sclerosis....Pages 310-322
Discussion....Pages 323-323
Distribution of Lymphocyte Subpopulations in the Peripheral Blood of MS Patients Under Corticotrophin Therapy....Pages 324-330
Cytological Findings in Cerebrospinal Fluid as Criteria of Process Activity in Multiple Sclerosis....Pages 331-335
Front Matter....Pages 87-87
Discussion....Pages 336-336
Multiple Sclerosis: Presence of Lymphatic Capillaries and Lymphoid Tissue in the Brain and Spinal Cord....Pages 337-339
A Histological and Histochemical Study of the Macroscopically Normal White Matter in Multiple Sclerosis....Pages 340-347
The Pathology of the Active Lesion....Pages 348-351
Discussion....Pages 352-354
Glia Cell Alterations in Multiple Sclerosis....Pages 355-359
Ultrastructural Changes in Peripheral Nerves in Multiple Sclerosis and Subacute Sclerosing Panencephalitis....Pages 360-364
c-AMPase and Lipids in Multiple Sclerosis and Normal Brain Myelin....Pages 365-367
Front Matter....Pages 369-369
Long Term Immunosuppressive Treatment with Azathioprine in Multiple Sclerosis. A 10 Year Trial with 77 Patients....Pages 371-375
Long-Term Treatment of Multiple Sclerosis with Azathioprine....Pages 376-380
Long-Term Azathioprine Therapy in Multiple Sclerosis....Pages 381-387
Azathioprine in Multiple Sclerosis. A Controlled Prospective Study....Pages 388-395
Prognostic Factors in Intensive Immunosuppressive Treatment of Chronic Progressive MS....Pages 396-400
Intensive Immunosuppression with Cyclophosphamide in Remittent Forms of Multiple Sclerosis. A Follow-Up of 134 Patients for 2–10 Years....Pages 401-406
A Pilot Study of Amantadine Treatment of Multiple Sclerosis....Pages 407-408
Discussion....Pages 409-415
A Synthetic Copolymer of Amino Acids in a Clinical Trial for MS Therapy....Pages 416-418
Studies on Myelin Basic Protein Administration in Multiple Sclerosis Patients....Pages 419-427
Studies on Myelin Basic Protein Administration in Multiple Sclerosis Patients....Pages 428-433
Discussion....Pages 434-435
Front Matter....Pages 369-369
Essential Fatty Acids and Immunity....Pages 436-441
Discussion....Pages 442-443
The Effect of Diet on Serum Linoleic Acid in MS....Pages 444-446
Metabolism of Myelin-Typical Long-Chain Fatty Acids....Pages 447-450
Observations in 166 Patients with Multiple Sclerosis After Thymectomy....Pages 451-453
Discussion....Pages 454-454
Front Matter....Pages 455-455
Correlation of the Course of MS and Histocompatibility Antigens....Pages 456-459
HLA Patterns in Multiple Sclerosis....Pages 460-464
Multiple Sclerosis Among Immigrants to Britain and in the Islands of Sicily and Malta....Pages 465-468
The HLA-D System in Multiple Sclerosis....Pages 469-475
HLA-Dw2-Associated C2 Hypocomplementemia in Multiple Sclerosis: A New Genetic Marker?....Pages 476-484
A Sib-Pair Double-Case Study of the Genetics of Multiple Sclerosis. An Interim Report on 34 Pairs of Affected Siblings....Pages 485-489
Discussion....Pages 490-494
The Geographic Distribution of Multiple Sclerosis: New Concepts....Pages 495-502
Epidemiological and Immunogenetic Studies of Multiple Sclerosis in Japan....Pages 503-508
Cerebrospinal Fluid Findings in Japanese Patients with Multiple Sclerosis....Pages 509-515
HLA Groups in Relation to Epidemiology....Pages 516-518
Clustering and Epidemic Occurrence of MS....Pages 519-524
Discussion....Pages 525-527
Epidemiological and Serological Findings in Multiple Sclerosis, Results of a 12-Year Study in Southern Lower Saxony....Pages 528-529
Front Matter....Pages 455-455
Studies on the Course of Multiple Sclerosis....Pages 530-534
MS in Switzerland — Canton Wallis....Pages 535-538
Epidemiological Research in MS in Italy and Optic Neuritic Risk Cases of MS....Pages 539-545
Optic Neuritis in Hannover — An Epidemiologic and Serogenetic Study....Pages 546-548
Some Features of MS in Pécs, Hungary....Pages 549-550
Discussion....Pages 551-551
Front Matter....Pages 553-553
IMAB-Enquête Concerning the Diagnostic Criteria for MS....Pages 555-563
The Role of Evoked Potentials in the Diagnosis of Multiple Sclerosis....Pages 564-568
Value of the Evoked Potential Examination in Diagnosis of MS....Pages 569-570
Pattern-Evoked Visual Potentials in 251 MS Patients in Relation to Ophthalmological Findings and Diagnostic Classification....Pages 571-577
Pattern and Flash Visual-Evoked Responses in Multiple Sclerosis....Pages 578-585
Quantitative Evaluation of Visual Disturbance in Optic Neuritis. A Follow-up Study of 30 Cases by Static Perimetry....Pages 586-588
Evaluation of Motor Deficits in Patients Suffering from Multiple Sclerosis....Pages 589-595
CT Scan in the Diagnosis and Assessment of the Course of MS....Pages 596-598
Quantitation and Assessment of the Course of Multiple Sclerosis. Some Remarks....Pages 599-602
Multiple Sclerosis Clinical Trials: A Comprehensive System for the Measurement and Evaluation of Neurologic Function....Pages 603-625
Clinicopathological and Epidemiological Documentation of Patients with Multiple Sclerosis....Pages 626-628
Taxonomy and Multiple Sclerosis....Pages 629-631
Discussion....Pages 632-637
Multiple Sclerosis: Generating Effective Human Services....Pages 638-646
Front Matter....Pages 553-553
Summary and Concluding Remarks....Pages 647-661
Panel Discussion....Pages 662-669
Back Matter....Pages 671-680